The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
CD95 ligand induces motility and invasiveness of apoptosis‐resistant tumor cells
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Self-citationIKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W., Young, D. B., Barbosa, M., Mann, M., Manning, A., et al. (1997) · Science · doi:10.1126/science.278.5339.860 · Cited by 2,040
The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal
Kelliher, M. A., Grimm, S., Ishida, Y., Kuo, F., Stanger, B. Z., & Leder, P. (1998) · Immunity · doi:10.1016/s1074-7613(00)80535-x · Cited by 1,102
Friesen, C., Herr, I., Krammer, P. H., & Debatin, K.-M. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 974
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
May, M. J., D'Acquisto, F., Madge, L. A., Glöckner, J., Pober, J. S., & Ghosh, S. (2000) · Science · doi:10.1126/science.289.5484.1550 · Cited by 680
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Fas transduces activation signals in normal human T lymphocytes.
Alderson, M. R., Armitage, R. J., Maraskovsky, E., Tough, T. W., Roux, E., Schooley, K., Ramsdell, F., & Lynch, D. H. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2231 · Cited by 521
Inhibition of Fas death signals by FLIPs
Tschopp, J., Irmler, M., & Thome, M. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80223-9 · Cited by 520
Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., & Nagata, S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2045 · Cited by 508
Kim, J., Yu, W., Kovalski, K., & Ossowski, L. (1998) · Cell · doi:10.1016/s0092-8674(00)81478-6 · Cited by 468
Caspase Activation Is Required for T Cell Proliferation
Kennedy, N. J., Kataoka, T., Tschopp, J., & Budd, R. C. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1891 · Cited by 459
Barnhart, B. C., Alappat, E. C., & Peter, M. E. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(03)00031-9 · Cited by 419
Self-citationThe Urokinase Plasminogen Activator System: Role in Malignancy
Duffy, M. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453559 · Cited by 400
Alam, A., Cohen, L. Y., Aouad, S., & Sékaly, R.-P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1879 · Cited by 390
Schmitt, M., Harbeck, N., Thomssen, C., et al. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657541 · Cited by 386
NF-κB in cancer: a marked target
Lin, A., & Karin, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00128-1 · Cited by 355
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back
Walker, P. R., Saas, P., & Dietrich, P. Y. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.4521 · Cited by 327
A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., & Bruggen, P. V. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.785 · Cited by 321
Fas engagement induces neurite growth through ERK activation and p35 upregulation
Desbarats, J., Birge, R. B., Mimouni-Rongy, M., Weinstein, D. E., Palerme, J.-S., & Newell, M. K. (2003) · Nature Cell Biology · doi:10.1038/ncb916 · Cited by 312
The role of Fas ligand in immune privilege
Green, D. R., & Ferguson, T. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35103104 · Cited by 284
Yebra, M., Parry, G. C. N., Strömblad, S., Mackman, N., Rosenberg, S., Mueller, B. M., & Cheresh, D. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.29393 · Cited by 242
Faouzi, S., Burckhardt, B. E., Hanson, J. C., Campe, C. B., Schrum, L. W., Rippe, R. A., & Maher, J. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m109791200 · Cited by 209
Cytotoxic drugs and the CD95 pathway
Friesen, C., Fulda, S., & Debatin, K.-M. (1999) · Leukemia · doi:10.1038/sj.leu.2401333 · Cited by 208
Park, D. R., Thomsen, A. R., Frevert, C. W., Pham, U., Skerrett, S. J., Kiener, P. A., & Liles, W. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6209 · Cited by 176
Hansen, S. K., Nerlov, C., Zabel, U., Verde, P., Johnsen, M., Baeuerle, P. A., & Blasi, F. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05043.x · Cited by 168
Toyoshima, F., Moriguchi, T., & Nishida, E. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.4.1005 · Cited by 156
The CD95 (APO-1/Fas) Receptor Activates NF- B Independently of Its Cytotoxic Function
Ponton, A., Clement, M., & Stamenkovic, I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8991 · Cited by 136
The biological role of the Fas/FasL system during tumor formation and progression
Ernst Reichmann, A. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00017-2 · Cited by 126
Two CD95 tumor classes with different sensitivities to antitumor drugs
Algeciras-Schimnich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L., & Peter, M. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034995100 · Cited by 118
Self-citationBlocking Caspase-3-Mediated Proteolysis of IKKβ Suppresses TNF-α-Induced Apoptosis
Tang, G., Yang, J., Minemoto, Y., & Lin, A. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00380-x · Cited by 113
Inactivation of Caspase-8 on Mitochondria of Bcl-xL-expressing MCF7-Fas Cells
Stegh, A. H., Barnhart, B. C., Volkland, J., Algeciras-Schimnich, A., Ning, K., Reed, J. C., & Peter, M. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108947200 · Cited by 109
Self-citationExtracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity
Aoki, K., Kurooka, M., Chen, J.-J., Petryniak, J., Nabel, E., & Nabel, G. (2001) · Nature Immunology · doi:10.1038/86336 · Cited by 104
Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.
Müschen, M., Ré, D., Bräuninger, A., Wolf, J., Hansmann, M., Diehl, V., Küppers, R., & Rajewsky, K. (2000) · PubMed · Cited by 103
Fas and Fas ligand interactions in malignant disease.
Owen‐Schaub, L. B., Chan, H. H. L., Cusack, J. C., Roth, J. A., & Hill, L. L. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.5 · Cited by 95
Non-apoptotic Signaling Pathways Activated by Soluble Fas Ligand in Serum-starved Human Fibroblasts
Ahn, J.-H., Park, S.-M., Cho, H.-S., Lee, M., Yoon, J., Vilček, J., & Lee, T. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107385200 · Cited by 95
Eichhorst, S. T., Müerköster, S. S., Weigand, M. A., & Krammer, P. H. (2001) · PubMed · Cited by 79
Newton, T. R., Patel, N. M., Bhat‐Nakshatri, P., Stauss, C. R., Goulet, R. J., & Nakshatri, H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18827 · Cited by 64
Jarad, G., Wang, B., Khan, S., Devore, J., Miao, H., Wu, K. L., Nishimura, S. L., Wible, B. A., Konieczkowski, M., Sedor, J. R., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204901200 · Cited by 41
Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer
Lee, J. K., Sayers, T. J., Back, T. C., Wigginton, J. M., & Wiltrout, R. H. (2003) · APOPTOSIS · doi:10.1023/a:1022918625509 · Cited by 39
Packham, G., Lahti, J. M., Fee, B. E., Gawn, J. M., Coustan‐Smith, E., Campana, D., Douglas, I., Kidd, V. J., Ghosh, S., & Cleveland, J. L. (1997) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400217 · Cited by 24
Gardnerova, M., Blanqué, R., & Gardner, C. (2000) · Current Drug Targets · doi:10.2174/1389450003349092 · Cited by 21
CD95L/FasL and its receptor CD95 (APO-1/Fas)
Peter, M. E., Barnhart, B. C., & Algeciras-Schimnich, A. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50042-9 · Cited by 16
Self-citation
Cited by
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
“In vitro motility assay was performed as described previously (Barnhart et al. 2004).”
MethodSelf-citationHow Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 717
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
Life and death in peripheral T cells
Krammer, P. H., Arnold, R., & Lavrik, I. N. (2007) · Nature Reviews Immunology · doi:10.1038/nri2115 · Cited by 653
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Metadata
- Authors
- Barnhart, B. C., Legembre, P., Pietras, E., Bubici, C., Franzoso, G., & Peter, M. E.
- Venue
- The EMBO Journal
- Published
- 2004-07-22
- Volume
- 23
- Issue
- 15
- Pages
- 3175-3185
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W2132954482
- Cited by
- 284
- References
- 46
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.